What Is Lixisenatide?

1. How does lixisenatide work?

Like every GLP-1 receptor agonist, it raises insulin when glucose is high, suppresses glucagon, slows gastric emptying, and reduces appetite. What sets it apart is how briefly it does so. The molecule is derived from exendin-4, the same lizard peptide behind exenatide, and it is cleared within hours rather than binding albumin for days the way liraglutide and semaglutide do.

That short exposure changes the clinical profile. A drug present for a few hours after a morning injection slows the stomach and blunts the glucose rise after breakfast, with its effect fading by evening. Long-acting agonists hold the receptor continuously, which lowers fasting glucose and produces the sustained appetite suppression behind their weight-loss indications. Lixisenatide never had one. It is a post-meal glucose drug, which is exactly the role it plays inside Soliqua next to a basal insulin that handles the fasting side.

2. What is the lixisenatide dose?

The 10 mcg start is for tolerability. If a dose is missed, the label says to take it within the hour before the next meal rather than double. Adlyxin shipped as two pens, a green starter pen delivering 10 mcg and a burgundy maintenance pen delivering 20 mcg, each with 14 doses. Inside Soliqua the lixisenatide dose is fixed to the insulin dose: 5 to 20 mcg alongside 15 to 60 units of glargine.

3. How much does lixisenatide lower blood sugar?

The GetGoal program established the drug in type 2 diabetes. Two representative trials:

Those are modest reductions by the standards of the long-acting drugs; semaglutide 1 mg lowers HbA1c by close to 2 percentage points in comparable settings. GetGoal-X is the head-to-head worth reading closely: lixisenatide matched exenatide’s twice-daily dosing on HbA1c within the noninferiority margin, produced slightly less weight loss (94.5 to 91.7 kg versus 96.7 to 92.9 kg), but caused less symptomatic hypoglycemia (2.5% vs 7.9%) and less nausea (24.5% vs 35.1%). In GetGoal-L, added to basal insulin, lixisenatide also cut insulin dose by 3.7 units/day and body weight by 1.3 kg versus placebo, without the added insulin-driven weight gain.

The comparison that matters for lixisenatide’s surviving product is LixiLan-O, where adding it to insulin glargine lowered HbA1c by 1.6 points against 1.3 for glargine alone, with the weight gain of insulin cancelled out and no separate weight-loss benefit from the lixisenatide component itself. The Soliqua page has those numbers.

4. Does lixisenatide reduce heart attacks and strokes?

No, and the trial that showed it was a landmark. ELIXA randomised 6,068 adults with type 2 diabetes who had an acute coronary syndrome within the previous 180 days to lixisenatide or placebo, and followed them for a median of 25 months.

Secondary results were as neutral as the primary one: hospitalization for heart failure occurred at the same rate (hazard ratio 0.96, 95% CI 0.75-1.17) and all-cause death was unchanged (hazard ratio 0.94, 95% CI 0.78-1.13). Lixisenatide was not associated with more pancreatitis, pancreatic neoplasms, or severe hypoglycemia than placebo. ELIXA settled the safety question the FDA had asked of every new diabetes drug since 2008, and it did so for the whole class. The benefit came later, from the long-acting drugs; the Victoza page covers LEADER and the semaglutide page SUSTAIN-6 and SELECT. Whether the difference reflects duration of action or the drugs themselves is unresolved.

5. What are the side effects of lixisenatide?

The label carries no boxed warning and no contraindication for medullary thyroid carcinoma, unlike liraglutide, semaglutide, dulaglutide, and tirzepatide. Section 13.1, Carcinogenesis, does report rodent findings: statistically significant increases in thyroid C-cell adenomas in mice and rats, and a numerical increase in C-cell carcinomas in rats. The warnings and precautions that do apply are the class set: pancreatitis, hypoglycemia when combined with insulin or a sulfonylurea, acute kidney injury from dehydration, hypersensitivity, and delayed absorption of oral medicines because of slower gastric emptying. The label also asks for closer monitoring in moderate to severe kidney impairment and does not recommend the drug in end-stage renal disease.

6. Pharmacokinetics, pregnancy, and drug interactions

The Adlyxin label puts a number on the short duration described above: median time to peak plasma concentration is 1 to 3.5 hours after a subcutaneous dose, and the drug is cleared mainly by glomerular filtration and proteolytic degradation, the peptide-breakdown route typical of exendin-4 derivatives, rather than liver metabolism.

Renal function changes the risk-benefit, not the dose:

Two label statements bear on use in pregnancy and children: Adlyxin should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus, based on animal studies showing visceral and skeletal defects at 1 to 6 times the clinical exposure; and safety and effectiveness have not been established in pediatric patients.

Because lixisenatide slows gastric emptying, the label gives specific timing rules for drugs that need it least. Oral contraceptives should be taken at least 1 hour before the lixisenatide injection or at least 11 hours after it. Oral drugs that depend on a threshold concentration to work, such as antibiotics, or where a delayed effect is undesirable, such as acetaminophen, should be taken at least 1 hour before the injection.

The pen itself has its own rules: refrigerate unopened pens at 36 to 46°F (2 to 8°C), never frozen. Once a pen is in use it can be kept at room temperature up to 86°F (30°C), but it must be discarded 14 days after first use regardless of how much remains in it, and it should stay in its original carton to protect it from light, with the cap replaced after every injection.

7. Where is lixisenatide now?

The standalone product lost to the weekly drugs on every axis: HbA1c, weight, cardiovascular benefit, and dosing convenience. Its survival in Soliqua reflects the one place a short-acting GLP-1 agonist has a distinct role: paired with a basal insulin, where it covers the meal that the insulin does not.

The EMA states the withdrawal was for commercial reasons, at Sanofi’s request, not for safety or efficacy, and it points to other GLP-1 receptor agonists as available alternatives across the EU.

A footnote outside diabetes. The molecule also had a second life in research. LIXIPARK, a phase 2 trial published in NEJM in April 2024, randomised 156 people with early Parkinson’s disease (diagnosed under 3 years, no motor complications) to daily lixisenatide or placebo for 12 months plus a 2-month washout. Both groups started at an MDS-UPDRS part III motor score of about 15. At 12 months, the lixisenatide group had improved by 0.04 points while the placebo group had worsened by 3.04 points, a difference of 3.08 points (95% CI 0.86 to 5.30, P=0.007).

The gap persisted after the washout: 17.7 versus 20.6 at 14 months. Nausea occurred in 46% of the lixisenatide group and vomiting in 13%. The authors call for a longer, larger trial; it is a hypothesis, not a treatment, and diabetes is still the only approved indication for lixisenatide.

For a log, Adlyxin and Soliqua entries are the same: product, date, dose, injection site, and the meal it preceded. How GLP-1 tracking works covers what to record.

8. Lixisenatide FAQ

• Does lixisenatide cause weight loss?

  It was never approved for weight loss. In GetGoal-X, lixisenatide produced slightly less weight loss than exenatide (94.5 to 91.7 kg versus 96.7 to 92.9 kg), and in GetGoal-L, added to basal insulin, it cut weight by 1.3 kg against placebo, enough to offset insulin-driven weight gain but not a weight-loss result in its own right. For an approved weight-loss GLP-1, see [semaglutide](/what-is-semaglutide) or [tirzepatide](/what-is-tirzepatide).

• Is lixisenatide still available?

  Not on its own in the U.S. Sanofi discontinued Adlyxin from January 1, 2023, and the EU brand Lyxumia's marketing authorisation was withdrawn in December 2025. Lixisenatide is still sold as the GLP-1 component of Soliqua 100/33, a fixed-ratio pen with insulin glargine.

• What is the lixisenatide dose?

  10 mcg once daily for 14 days, then 20 mcg once daily, injected within 60 minutes before the first meal of the day. A missed dose is taken within the hour before the next meal, not doubled.

• How is lixisenatide different from Ozempic?

  Duration. Lixisenatide's half-life is about 3 hours, so it is dosed daily and acts mainly on the meal it precedes. Semaglutide's half-life is about a week, so it is dosed weekly and lowers fasting glucose and weight far more. Lixisenatide produced no weight-loss indication and no cardiovascular benefit in ELIXA; semaglutide has both.

• Does lixisenatide reduce heart attacks?

  No. ELIXA randomised 6,068 adults with type 2 diabetes who had a recent acute coronary syndrome and followed them for a median of 25 months. The primary cardiovascular endpoint occurred in 13.4% on lixisenatide and 13.2% on placebo, hazard ratio 1.02. It proved safety, not benefit, and it was the first GLP-1 cardiovascular outcomes trial to report.

• What are the side effects of lixisenatide?

  Mostly gastrointestinal: nausea in 25% versus 6% on placebo, vomiting in 10% versus 2%, plus headache, diarrhea, and dizziness at lower rates. It carries no thyroid C-cell boxed warning, but the class warnings on pancreatitis, hypoglycemia with insulin or a sulfonylurea, and kidney injury from dehydration apply.

• Why does lixisenatide have no thyroid boxed warning?

  The Adlyxin label carries no boxed warning and no medullary thyroid carcinoma contraindication, unlike liraglutide, semaglutide, and tirzepatide. That is not because the rodent finding was absent: the label's carcinogenicity section (13.1) reports statistically significant increases in thyroid C-cell adenomas in mice and rats, and a numerical increase in C-cell carcinomas in rats. The other class warnings, on pancreatitis, hypoglycemia with insulin or sulfonylureas, and kidney injury from dehydration, apply.

9. Sources